
ASRT Stock Forecast & Price Target
ASRT Analyst Ratings
Bulls say
Assertio Holdings Inc. is poised for a favorable outlook following its acquisition by Garda Therapeutics, which presents significant premiums of 34.6% to the unaffected stock price and up to 62.2% to the 60-day volume-weighted average price, indicating strong market confidence in its long-term prospects. Additionally, the completion of the reverse split eliminates the risk of delisting from NASDAQ, ensuring compliance with minimum bid price requirements and enhancing stock stability. Furthermore, the strategic divestiture of non-Rolvedon assets to Cosette Pharmaceuticals enables Assertio to concentrate on its core oncology products, potentially optimizing its operational efficiencies and market positioning.
Bears say
Assertio Holdings Inc faces significant challenges that negatively impact its stock outlook, primarily due to the potential inability to gain additional market share for key products like ROLVEDON and Sympazan amid increasing competition. The company's recent loss on impairment of intangible assets, totaling $5.2 million, highlights concerns regarding its asset valuation and future growth prospects, particularly with legacy products losing market exclusivity. Furthermore, the anticipated decline in revenue from non-core products and a heightened risk of equity dilution creates an uncertain financial environment that undermines investor confidence.
This aggregate rating is based on analysts' research of Assertio Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.
ASRT Analyst Forecast & Price Prediction
Start investing in ASRT
Order type
Buy in
Order amount
Est. shares
0 shares